Analyst Ratings For NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)

.

Some recent analyst ratings include

• 4/16/2018-Morgan Stanley Upgrade from a “Equal Weight ➝ Overweight” rating to a “” rating.
• 4/16/2018-William Blair Reiterated Rating of Buy.
• 3/5/2018-Citigroup Reiterated Rating of Buy ➝ Buy.
• 3/1/2018-Cann Reiterated Rating of Buy.
• 2/22/2018-CIBC initiated coverage with a Outperform ➝ Outperform rating.

• On 4/25/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.12 per share and the total transaction amounting to $1,966,800.00.
• On 4/25/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $131.23 per share and the total transaction amounting to $404,450.86.
• On 4/24/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $131.65 per share and the total transaction amounting to $223,805.00.
• On 4/20/2018 Lori Anne Kunkel, Director, sold 5,000 with an average share price of $132.68 per share and the total transaction amounting to $663,400.00.
• On 3/14/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.54 per share and the total transaction amounting to $1,973,100.00.
• On 3/14/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $131.41 per share and the total transaction amounting to $405,005.62.
• On 3/13/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $131.33 per share and the total transaction amounting to $223,261.00.

Recent Trading Activity for NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)
Shares of NASDAQ:LOXO – Loxo Oncology closed the previous trading session at 126.60 up +2.43 1.96% with shares trading hands.